ES2126265T3 - Tableta de accion retardada con un cierto contenido de diclorofenaco de sodio. - Google Patents

Tableta de accion retardada con un cierto contenido de diclorofenaco de sodio.

Info

Publication number
ES2126265T3
ES2126265T3 ES95913097T ES95913097T ES2126265T3 ES 2126265 T3 ES2126265 T3 ES 2126265T3 ES 95913097 T ES95913097 T ES 95913097T ES 95913097 T ES95913097 T ES 95913097T ES 2126265 T3 ES2126265 T3 ES 2126265T3
Authority
ES
Spain
Prior art keywords
certain content
delayed action
action tablet
sodium dichlorophene
dichlorophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913097T
Other languages
English (en)
Other versions
ES2126265T5 (es
Inventor
Wilfried Fischer
Karin Klokkers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6512563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2126265(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hexal AG filed Critical Hexal AG
Publication of ES2126265T3 publication Critical patent/ES2126265T3/es
Application granted granted Critical
Publication of ES2126265T5 publication Critical patent/ES2126265T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION TRATA DE UNA TABLETA DE LIBERACION RETARDADA CONTENIENDO DICLOFENAC-NA COMO PRINCIPIO ACTIVO Y METILHIDROXIPROPIL-CELULOSA COMO AGENTE RETARDANTE.
ES95913097T 1994-03-11 1995-03-13 Tableta de accion retardada con un cierto contenido de diclofenaco de sodio. Expired - Lifetime ES2126265T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4408326 1994-03-11
DE4408326A DE4408326A1 (de) 1994-03-11 1994-03-11 Retardtablette mit einem Gehalt an Diclofenac-Na

Publications (2)

Publication Number Publication Date
ES2126265T3 true ES2126265T3 (es) 1999-03-16
ES2126265T5 ES2126265T5 (es) 2004-10-16

Family

ID=6512563

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913097T Expired - Lifetime ES2126265T5 (es) 1994-03-11 1995-03-13 Tableta de accion retardada con un cierto contenido de diclofenaco de sodio.

Country Status (14)

Country Link
US (1) US5874107A (es)
EP (1) EP0749304B9 (es)
JP (1) JPH09509953A (es)
AT (1) ATE173399T1 (es)
AU (1) AU692534B2 (es)
CA (1) CA2185242C (es)
DE (2) DE4408326A1 (es)
DK (1) DK0749304T4 (es)
ES (1) ES2126265T5 (es)
FI (1) FI118294B (es)
GR (1) GR3029278T3 (es)
NO (1) NO317396B1 (es)
PL (1) PL177607B1 (es)
WO (1) WO1995024188A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
AU3860797A (en) * 1997-07-16 1999-02-10 Antrin Research Limited Pharmaceutical formulations for oral administration
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
JP2006515008A (ja) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド 経口投与のためのミルナシプランの多粒子状組成物
US8107531B2 (en) * 2003-09-07 2012-01-31 Microsoft Corporation Signaling and repeat padding for skip frames

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786503A (en) † 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5236713A (en) * 1987-10-21 1993-08-17 Teikoku Seiyaku Kabushiki Kaisha Preparation for intermittently releasing active agent applicable to oral cavity
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata

Also Published As

Publication number Publication date
EP0749304A1 (de) 1996-12-27
PL316196A1 (en) 1996-12-23
NO317396B1 (no) 2004-10-25
DE4408326A1 (de) 1995-09-14
EP0749304B9 (de) 2006-03-08
JPH09509953A (ja) 1997-10-07
US5874107A (en) 1999-02-23
DE59504270D1 (de) 1998-12-24
FI963567A0 (fi) 1996-09-10
ATE173399T1 (de) 1998-12-15
GR3029278T3 (en) 1999-05-28
NO963796L (no) 1996-11-06
DK0749304T4 (da) 2004-03-29
NO963796D0 (no) 1996-09-10
PL177607B1 (pl) 1999-12-31
AU2069595A (en) 1995-09-25
EP0749304B2 (de) 2004-03-03
CA2185242C (en) 2004-11-23
DK0749304T3 (da) 1999-08-02
AU692534B2 (en) 1998-06-11
EP0749304B1 (de) 1998-11-18
FI963567L (fi) 1996-09-10
CA2185242A1 (en) 1995-09-14
ES2126265T5 (es) 2004-10-16
FI118294B (fi) 2007-09-28
WO1995024188A1 (de) 1995-09-14

Similar Documents

Publication Publication Date Title
PT1238659E (pt) Libertacao sustentada de um agente activo utilizando um sistema implantavel
ID27504A (id) Formulasi oral baru
ES2153836T3 (es) Composicion enmascaradora del sabor de agentes farmaceuticos amargos.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
ES2132547T3 (es) Solucion acuosa concentrada de argatroban.
ATE239431T1 (de) Abgabesystem bestehend aus einem vaginaschwamm
DK0810856T3 (da) Med bånd forsynet doseringsform af aktivt middel med forlænget frigivelse
ATE460921T1 (de) Medikamenthaltige zusammensetzung in aerosolform
ES2159591T3 (es) Composicion de liberacion controlada.
ES2176684T3 (es) Nuevas asociaciones de principios activos que contienen clopidogrel y un antitrombotico.
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
ES2130420T3 (es) Preparado transdermico de sustancia activa.
BR9810495A (pt) Composição farmacêutica
ES2193515T3 (es) Composicion farmaceutica que comprende un compuesto triciclico con mejor estabilidad, absortividad y escaso potencial irritativo.
DE60023107D1 (de) Zubereitungen mit verbesserter kontrollierter freisetzung
ES2139002T3 (es) Terapia medicamentosa citotoxica.
KR970702734A (ko) 안과용 조성물에서 아미도아민의 용도(use of amidoamines in ophthalmic compositions)
NO20011217D0 (no) Doseringsform omfattende væskeformulering
CO4700420A1 (es) Formulacion transdermica
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
PT1079839E (pt) Agente terapeutico contra constipacoes contendo a isomaltose como principio activo
ES2156220T3 (es) Preparacion transdermica que contiene un metabolito de loratidina con accion antihistaminica.
MX24039A (es) Composiciones farmaceuticas que contienen una calcitonina como principio activo.
ES2171669T3 (es) Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 749304

Country of ref document: ES